An individual gene profile provides a window into a person’s medical future, by examining DNA samples, but what are the best ways of regulating this developing technology? LSIPR looks at the challenges and possible solutions.
The technology of genetic screening has come on leaps and bounds since the Human Genome Project finished sequencing the entire human genome, after 13 years’ work, in 2003.
Now direct-to-consumer genetic testing companies can look at sections of your genome to determine risks of developing certain diseases, and deliver the results in a matter of weeks.
California-based 23andMe offers such a service. Describing itself as the largest DNA ancestry service in the world, 23andMe’s personal genome service (PGS) will analyse the DNA it receives from the saliva kit it sends and provide a detailed report about a person’s risks of developing certain diseases.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
direct-to-consumer genetic tests, Personal Genome Service, regulation, 23andMe, FDA